hsCRP: The Inflammation Marker That Connects Metabolic Disease to Heart Attacks

There’s a version of cardiovascular disease that doesn’t start with high cholesterol. It starts with inflammation.

More precisely, it starts with the low-grade, chronic, systemic inflammation that is almost invisible on standard lab work — the kind that doesn’t produce fever, doesn’t show up in a white blood cell count, and doesn’t make you feel sick. It just quietly erodes arterial walls, destabilizes plaques, and drives the insulin resistance that accelerates every other metabolic risk factor you have.

High-sensitivity C-reactive protein — hsCRP — is one of the cleanest ways we have to measure that inflammatory burden. It is validated, inexpensive, widely available, and consistently predictive of cardiovascular events, type 2 diabetes, and all-cause mortality in large prospective studies. It is also routinely absent from standard annual bloodwork.

That gap is one I want to close for you.

---

What hsCRP Actually Measures

C-reactive protein is an acute-phase reactant — a protein produced by the liver in response to inflammatory signaling, primarily interleukin-6 (IL-6). When your body detects tissue damage, infection, or cellular stress, IL-6 is released and the liver responds by producing CRP within hours.

Standard CRP tests measure a range relevant to acute illness — infections, autoimmune flares, surgical trauma. Those levels can range from 5 to well above 100 mg/L. That test is useful in an emergency department, not in a cardiovascular risk clinic.

High-sensitivity CRP (hsCRP) uses a more sensitive assay calibrated to detect the much lower levels — typically 0.1 to 10 mg/L — that characterize chronic, low-grade systemic inflammation. These levels are too low to signal acute illness, but they are clinically meaningful for long-term risk stratification in people who feel perfectly well.

The distinction between standard CRP and hsCRP is not trivial. They are different tests using different assay methods. A standard CRP result of “negative” or “<5 mg/L” tells you nothing about your chronic inflammatory burden. You need to specifically request hsCRP.

Risk Stratification

The American Heart Association and CDC published a consensus statement establishing the following cardiovascular risk categories for hsCRP:

hsCRP Level	Cardiovascular Risk Category
< 1.0 mg/L	Low
1.0 – 3.0 mg/L	Average
> 3.0 mg/L	High
> 10 mg/L	Possible acute process — retest after resolution

Clinical Callout: If your hsCRP comes back above 10 mg/L, do not use that result for chronic risk stratification. A level that high usually indicates an acute inflammatory process — an infection, injury, or autoimmune flare. Wait 2–4 weeks and retest. The chronic low-grade inflammation we’re measuring for cardiovascular risk sits in the 1–10 mg/L range.

---

Why hsCRP Predicts Cardiovascular Disease

The mechanism connecting inflammation to atherosclerosis is well-established. Atherosclerosis is not simply a cholesterol storage problem — it is fundamentally an inflammatory disease. The process begins when ApoB-containing lipoprotein particles penetrate the arterial endothelium and become oxidized. Oxidized LDL particles trigger an immune response: monocytes infiltrate the arterial wall, differentiate into macrophages, engulf the oxidized lipoproteins, and become foam cells — the building blocks of arterial plaque.

Chronic systemic inflammation accelerates every step of this process. Inflammatory cytokines increase endothelial permeability, making it easier for lipoprotein particles to penetrate. They upregulate adhesion molecules that recruit more monocytes. They promote plaque instability — it’s not the largest plaques that cause most heart attacks, but the most inflamed ones, which rupture and trigger acute clots.

hsCRP is a downstream marker of this inflammatory cascade. Elevated hsCRP doesn’t cause atherosclerosis directly — CRP itself appears to have modest atherogenic properties, but its primary value is as a signal of the underlying inflammatory milieu that drives plaque progression and instability.

---

The JUPITER Trial: The Landmark Evidence

The most consequential piece of clinical evidence on hsCRP came from the JUPITER trial, published in the New England Journal of Medicine in 2008 and led by Dr. Paul Ridker at Brigham and Women’s Hospital.

JUPITER enrolled 17,802 apparently healthy adults with LDL cholesterol below 130 mg/dL — below the threshold that would normally prompt statin therapy — but with hsCRP of 2.0 mg/L or higher. Half received rosuvastatin 20 mg; half received placebo.

The trial was stopped early because the results were so compelling. Rosuvastatin reduced the primary endpoint — a composite of cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, and arterial revascularization — by 44% compared to placebo. Cardiovascular mortality was reduced by 47%. All-cause mortality fell by 20%.

What JUPITER demonstrated is that elevated hsCRP identifies a population at meaningful cardiovascular risk that standard cholesterol testing misses entirely. These were people with “normal” LDL who were not candidates for statin therapy by conventional criteria. Their inflammatory burden — not their cholesterol — was the signal.

The 2018 AHA/ACC cholesterol guidelines incorporate this evidence directly: hsCRP ≥2.0 mg/L is listed as a “risk-enhancing factor” that should tip borderline-risk patients toward statin therapy. The 2023 AHA PREVENT risk equations include hsCRP as an optional enhancer for cardiovascular risk prediction.

---

The Metabolic Connection: Why Visceral Fat Drives Inflammation

Here is where hsCRP becomes most relevant for the PrecisionOptimize audience, because the most common driver of chronically elevated hsCRP in otherwise healthy adults isn’t infection or autoimmune disease. It’s metabolic dysfunction — specifically visceral adiposity and insulin resistance.

Visceral fat — the fat stored around your organs, not under your skin — is metabolically active in a specifically harmful way. Visceral adipocytes (fat cells) secrete large amounts of IL-6, TNF-alpha, and other pro-inflammatory cytokines directly into the portal circulation, exposing the liver to a constant inflammatory signal. The liver responds by producing more CRP.

This creates a measurable and consistent pattern: patients with elevated HOMA-IR (insulin resistance), high waist circumference, elevated triglycerides, and low HDL — the metabolic syndrome phenotype — almost invariably have hsCRP above 2.0 mg/L. The inflammation isn’t a separate problem. It’s the same problem expressing itself through a different biomarker.

Clinical Callout: If your hsCRP is elevated and you don’t have an obvious inflammatory condition, the first place to look is your metabolic health. Get a fasting insulin level. Measure your waist circumference. Check your triglycerides and HDL. In my experience, elevated hsCRP in an otherwise asymptomatic patient is frequently the first visible signal of insulin resistance — showing up before the glucose and HbA1c numbers move.

Other significant drivers of chronic hsCRP elevation include untreated obstructive sleep apnea (one of the most underappreciated inflammatory conditions in medicine), periodontal disease, chronic psychological stress, and smoking.

---

hsCRP and Type 2 Diabetes Risk

The relationship between inflammation and T2DM is bidirectional. Insulin resistance drives inflammation; inflammation worsens insulin resistance. hsCRP independently predicts the development of type 2 diabetes, even after adjusting for traditional risk factors.

In the Women’s Health Study, women in the highest quartile of hsCRP had a relative risk of developing T2DM over 4 years more than 15 times higher than women in the lowest quartile. This is a strikingly large risk gradient.

The mechanism: inflammatory cytokines — particularly TNF-alpha and IL-6 — directly impair insulin receptor signaling, promoting insulin resistance at the cellular level. Chronic inflammation also promotes beta-cell apoptosis, gradually eroding the pancreatic reserve needed to compensate for insulin resistance.

For anyone tracking HOMA-IR as a metabolic health marker, hsCRP is a natural complement. They measure different but overlapping facets of the same underlying dysfunction.

---

How to Get Tested

hsCRP is available through virtually all standard labs and most direct-to-consumer platforms. Through Ulta Lab Tests or Walk-In Lab, the test costs approximately $10–20. Function Health includes it as part of their comprehensive panel.

The critical point: order hsCRP, not standard CRP. They require different assay methods and the result in one cannot be used to interpret the other. When ordering online, search for “high-sensitivity CRP” or “hsCRP” — the test names vary slightly by lab but all refer to the same sensitive assay.

Testing ideally in a fasted, healthy baseline state — not during or shortly after an acute illness, injury, or significant physical stress. A single markedly elevated result (>10 mg/L) warrants a retest rather than immediate clinical conclusions.

---

What Actually Lowers hsCRP

Let me be direct here: the interventions that most reliably lower hsCRP are the interventions that address the underlying metabolic dysfunction. There is no supplement that fixes chronic inflammation driven by visceral adiposity and insulin resistance.

Weight Loss

The most potent intervention. A 10% reduction in body weight in overweight and obese patients reliably reduces hsCRP by 20–40%. The mechanism is straightforward — less visceral fat means less IL-6, means less hepatic CRP production. Weight loss achieved through any sustained method (caloric restriction, GLP-1 therapy, bariatric surgery) produces similar hsCRP reductions.

Aerobic and Resistance Exercise

Both forms of exercise reduce hsCRP, independent of weight change. Aerobic exercise appears to reduce circulating inflammatory cytokines through multiple mechanisms including improved endothelial function, reduced sympathetic nervous system tone, and direct anti-inflammatory myokine release from muscle tissue. Resistance training’s anti-inflammatory effects are partly mediated by improved insulin sensitivity and reduced visceral fat over time.

Omega-3 Fatty Acids

Long-chain omega-3 fatty acids (EPA and DHA) — from fish oil or prescription agents like icosapent ethyl (Vascepa) — have meaningful anti-inflammatory effects via multiple pathways, including competitive inhibition of arachidonic acid metabolism and production of pro-resolving lipid mediators. Meta-analyses of omega-3 supplementation consistently show reductions in hsCRP of 0.3–0.5 mg/L on average, with larger reductions in patients with higher baseline inflammation. At the doses used in clinical trials, you need 2–4 grams of EPA+DHA daily for meaningful anti-inflammatory effect — this is higher than most retail fish oil supplements deliver.

Sleep

Untreated obstructive sleep apnea produces pronounced elevations in hsCRP. CPAP therapy consistently reduces hsCRP in patients with confirmed OSA. Even in patients without diagnosed sleep apnea, consistently poor sleep quality and short sleep duration are independently associated with higher hsCRP levels. This is one of the few risk factors where the intervention is purely behavioral and has no significant side effects.

Statins

Statins have pleiotropic anti-inflammatory effects beyond their LDL-lowering mechanism. Rosuvastatin in the JUPITER trial reduced hsCRP by approximately 37% alongside its LDL-lowering effects. For patients who are candidates for statin therapy based on cardiovascular risk, the hsCRP reduction is an additional benefit. For patients with elevated hsCRP but low LDL, JUPITER’s data provide a specific evidence base for statin initiation.

What Doesn’t Work (Well)

Low-dose aspirin reduces hsCRP modestly but its primary mechanism is antiplatelet, not anti-inflammatory at typical doses. Standard dietary advice (“eat more vegetables”) has modest effects in research settings. Antioxidant supplements have essentially no consistent evidence of hsCRP reduction in well-designed trials.

---